Valenza Trial Header with person


Participate in a kidney disease clinical trial researching
a new potential primary membranous nephropathy treatment.


Primary membranous nephropathy (PMN), also known as idiopathic membranous nephropathy, is a type of autoimmune glomerular disease and is one of the leading causes of non-diabetic nephrotic syndrome. PMN causes the body to lose considerable amounts of protein in the urine (called proteinuria) and can lead to impaired kidney function over time.


The only way to differentiate primary membranous nephropathy from other primary kidney conditions is to have a kidney biopsy, a procedure in which doctors examine a tiny portion of the kidney tissue.
  • Testing for circulating anti-PLA2R antibodies in the blood
  • Urinalysis: determines the amount of protein in the urine
  • Blood work: determines levels of creatinine, albumin, cholesterol, and many other factors examined to rule out other causes
  • Glomerular filtration rate (GFR): Your GFR estimates your kidney function by calculating blood creatinine levels with urine protein levels
  • Ultrasound: sometimes performed to get a closer look at the kidneys

What are the Current Primary Membranous Nephropathy treatments?

There are currently no FDA-approved medicines to treat primary membranous nephropathy (PMN). The standard treatment for PMN is prednisone, a corticosteroid aimed at decreasing proteinuria.

How Can VB119 Help You?

VB119, a potential treatment of proteinuria, works by lowering the activity of certain parts of the body’s own immune system that may be causing it to harm your kidneys and release protein in the urine. When the body loses a lot of protein in the urine, it can cause further kidney damage, poor nutrition, body swelling with weight gain, and feeling tired. The body’s immune system’s B-cells are designed to make proteins called antibodies that help to fight infections. However, in PMN, some of these B cells make antibodies that target the kidneys damaging the filters in the kidneys causing them to leak protein in the urine. VB119 is meant to decrease B-cells to stop them from making these antibodies and help decrease the protein in the urine. This should slow the worsening of kidney damage as well as improving the other symptoms of the disease such as fluid retention and swelling.


Eligible participants will need to visit the study center several times over a 2-year period. There is a possibility to complete some visits at your home by research staff if you are unable to travel to the study center. All participants will receive the study drug (VB119). Study drug will be given through the participant’s vein (IV) twice over a 2-week period and participants may receive 2 additional doses later in the study if eligible. Several tests and assessments will be performed to monitor the participant’s health. These assessments will include:
  • Collection of medical history and a list of any medications currently taken
  • Check vital signs, such as, blood pressure, heart rate, breathing rate, and temperature
  • Undertake a physical examination
  • Collection of blood and urine throughout the study
  • Collection of electrocardiogram (ECG)

If you are a primary membranous nephropathy patient or clinical investigator in the US and are interested in learning more about our study, please contact for more information.